Recombinant Cynomolgus CD79B protein, His-Avi-tagged, Biotinylated

Cat.No. : CD79B-2990C
Product Overview : Biotinylated Recombinant Cynomolgus CD79B protein(Ala 30-Asp 161), fused with His and Avi tag, was expressed in HEK293.
  • Specification
  • Gene Information
  • Related Products
  • Download
Source : HEK293
Species : Cynomolgus
Tag : His&Avi
Form : Lyophilized from 0.22 μm filtered solution in PBS, 0.2 M Arginine, pH7.4. Normally trehalose is added as protectant before lyophilization.
Molecular Mass : This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).The protein has a calculated MW of 18.9 kDa. The protein migrates as 30-35 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Protein Length : Ala 30-Asp 161
Endotoxin : Less than 1.0 EU per μg by the LAL method.
Purity : >90% as determined by SDS-PAGE.
Storage : For long term storage, the product should be stored at lyophilized state at-20°C or lower.Please avoid repeated freeze-thaw cycles. This product is stable after storage at:-20°C to-70°C for 12 months in lyophilized state;-70°C for 3 months under sterile conditions after reconstitution.
Reconstitution : It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4°C before opening to recover the entire contents.

For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.

Inquiry

  • Reviews
  • Q&As

Customer Reviews (3)

Write a review
Reviews
04/26/2023

    Renowned for its reliability and consistency, this protein offers researchers the confidence to achieve accurate and reproducible results in their studies.

    11/16/2021

      The CD79B protein comes highly recommended for its outstanding performance in ELISA assays.

      10/26/2018

        One notable advantage of the CD79B protein is the excellent technical support provided by its manufacturer.

        Q&As (5)

        Ask a question
        How does CD79B-targeted immunotherapy differ from traditional chemotherapy in treating B cell malignancies? 03/27/2021

        CD79B-targeted immunotherapy aims to specifically target B cells, potentially reducing side effects compared to non-specific chemotherapy.

        How does CD79B contribute to the development of personalized treatment strategies for B cell diseases? 01/12/2021

        Analyzing CD79B expression helps tailor treatment plans, allowing for more personalized and effective approaches.

        Can CD79B be used as a biomarker for minimal residual disease in B cell malignancies? 05/13/2018

        Yes, monitoring CD79B levels can aid in detecting minimal residual disease, providing insights into treatment response.

        Are there any challenges or limitations associated with relying on CD79B as a diagnostic marker? 03/02/2017

        Variability in CD79B expression among different B cell disorders may pose challenges in its use as a standalone diagnostic marker.

        Are there any clinical trials investigating the therapeutic potential of CD79B-targeted drugs? 01/22/2016

        Yes, several clinical trials are exploring the efficacy of CD79B-targeted drugs in various B cell disorders.

        Ask a Question for All CD79B Products

        Required fields are marked with *

        My Review for All CD79B Products

        Required fields are marked with *

        0

        Inquiry Basket

        cartIcon
        logo

        FOLLOW US

        Terms and Conditions        Privacy Policy

        Copyright © 2024 Creative BioMart. All Rights Reserved.

        Contact Us

        • /
        • Service lnquiry:

        Stay Updated on the Latest Bioscience Trends